Even In Clinical Studies, Big Potential For MRI-Guided Procedures

J. King profile picture
J. King

On Monday, cancer therapy developer Tocagen announced a partnership with MRI Interventions (MRIC.OB) and BrainLab AG as part of Tocagen's Phase I/II study of brain cancers in their most aggressive form - high grade gliomas. The study applies Tocagen's Toca 511 retroviral replicating vector (RRV) directly to the brain tumor in tandem with an oral flucytosine, Toca FC, to more aggressively track and attack the affected region.

Glioblastoma multiforme, a form of malignant brain tumor, spreads in microscopic tendrils that can be nearly impervious to removal; even the smallest amount of cells left behind can regrow. But developers hope that the RRC and flucytosine together can accurately and efficiently eliminate the malignancy.

Tocagen will be utilizing MRI Intervention's proprietary technology, ClearPoint Neuro Intervention System, to intracranially apply the Toca-511 RRV therapy. ClearPoint is the only minimally invasive technology of its kind. Using an existing MRI suite, the system allows doctors a real-time, MRI-guided look inside the brain during neuro procedures; the detail and oversight ability are vastly superior to previous technology.

The implications of this alliance, however, are broader than this trial alone. There are currently more than 250 actively recruiting studies for indications of glioblastoma in the United States. Celldex Therapeutics. (CLDX), for example, is recruiting 95 patients to study the effects of their experimental rindopepimut vaccine on glioblastoma. Exelexis' (EXEL) ongoing Phase II Cabozantinib study enrolled 225 patients for treatment of glioblastoma multiforme. Pfizer's (PFE) pipeline product Sunitinib is in a pilot study to test use in indications of glioblastoma. The biggest hurdle for Sunitinib, and for most blood-borne drugs in cerebral indications, is the blood-brain barrier (BBB), the body's natural defense against pathogens entering the brain. Intracranial procedures are one of the few options in bypassing the BBB for direct application. While these studies may

This article was written by

J. King profile picture
J. King works as an investigational journalist but has a passion for research-based investing and trading.

Recommended For You

Comments (3)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.